. Author manuscript; available in PMC: 2013 Aug 1.

Published in final edited form as: Curr Opin Virol. 2012 Jun 5;2(4):419–425. doi: 10.1016/j.coviro.2012.05.003

Table 3.

Serum neutralizing antibody (SNA) seroresponse rates and vaccine efficacy (Prot) against severe RVGE in selected RV5 studies.

Strain Serotype	Bangladesh and Vietnam OPV [27]		Ghana, Kenya and Mali OPV [28]		Latin America OPV [30]		US and Finland No OPV [5]
	% SNA	% Prot	% SNA	% Prot	% SNA	% Prot	% SNA	% Prot
G1	32.1	46.2	18.5	32.3	59.9	NR	76	74.9^*
G2	9.9	29.2	9	27.1	36.3	NR	34.3	63.4^*
G3	28.2	67	6.3	62.3	29.3	NR	22.1	82.7^*
G4	18.3	NR	26.5	NR	50.9	NR	54.1	48.1^*
P1A [8]	27.5	49.7	14.4	36.1	43.9	NR	53.7	NR

Clinical efficacy calculated for RVGE of any severity.

NR = not reported.